Mvabea Market Report 2026

Mvabea Market Overview

• The Mvabea market growth in the historic period has been driven by recurrent ebola outbreaks in endemic regions, global emergency response initiatives • Market expansion is supported by increasing focus on pandemic preparedness, rising funding for emerging infectious disease vaccines • Growth Driver: Rising Incidence Of Ebola Driving Growth In The Market • Market Trend: Regulatory Approval Of Mvabea Expands Treatment Options For Adolescents Aged 12 To 17 Years • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Mvabea Market?

Mvabea is a component of a two-dose Ebola vaccine regimen developed to protect against the Zaire Ebola virus species. It works alongside Zabdeno (Ad26.ZEBOV) and is administered as the second dose to enhance the immune response. Mvabea uses a modified vaccinia Ankara (MVA) vector to deliver viral proteins and stimulate immunity. The main product types of mvabea are mvabea (MVA-BN-Filo) and zabdeno (Ad26.ZEBOV). Mvabea is a vaccine designed to protect against Ebola virus disease, specifically caused by Zaire ebolavirus. Its applications are ebola virus disease prevention and outbreak control efforts, and it is used by various end users such as government organizations, healthcare providers, and research institutions.

What Is The Mvabea Market Growth Forecast?

The growth in the forecast period can be attributed to increasing focus on pandemic preparedness, rising funding for emerging infectious disease vaccines, expansion of stockpiling strategies, growing use of vector-based vaccine technologies, increased global health security investments. Major trends in the forecast period include increasing deployment of ebola vaccination programs, rising focus on outbreak preparedness, expansion of two-dose vaccine regimens, growing investment in viral vector platforms, enhanced international collaboration for disease control.

Global Mvabea Market Segmentation

1) By Product Type: Mvabea (MVA-BN-Filo), Zabdeno (Ad26.ZEBOV) 2) By Application: Ebola Virus Disease Prevention, Outbreak Control Efforts 3) By End User: Government Organizations, Healthcare Providers, Research Institutions

What Is The Driver Of The Mvabea Market?

The rising incidence of ebola is expected to propel the growth of the mvabea market going forward. Ebola refers to a highly contagious and often deadly disease caused by the Ebola virus, a member of the filovirus family. The rising incidence of Ebola can be due to increased human-wildlife interactions, urbanization, weakened healthcare systems, and challenges in rapid disease detection and response. MVABE (Monoclonal Vaccine Against Ebola) is utilized in the fight against Ebola by providing targeted immunity through antibodies that specifically bind to and neutralize the Ebola virus, helping to prevent infection or reduce its severity in individuals exposed to the virus. For instance, in April 2025, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, Uganda declared the end of a Sudan virus disease outbreak that began on 30 January 2025, with 14 cases and 4 deaths, compared with the 164 cases and 77 deaths reported in the previous Sudan-strain Ebola outbreak in 2022. Therefore, the rising incidence of ebola is driving the growth of the mvabea industry.

Key Players In The Global Mvabea Market

Major companies operating in the mvabea market are Johnson & Johnson

Global Mvabea Market Trends and Insights

A key trend in the MVA-BN market is obtaining regulatory approvals for its mpox vaccine, Imvanex (MVA-BN), for use in adolescents aged 12 to 17 years. Regulatory approvals refer to formal authorizations granted by governmental or regulatory bodies that allow a drug, medical device, or treatment to be marketed and used by the public. For instance, in September 2024, Bavarian Nordic, a Denmark-based biotechnology company, received FDA approval and EMA authorization for its mpox vaccine targeting 12-17 years of age group. The MVA-BN vaccine, marketed under JYNNEOS, IMVAMUNE, and IMVANEX, is a non-replicating live virus vaccine suitable for immunocompromised individuals. It is approved for both mpox and smallpox prevention, demonstrating approximately 76% effectiveness with a single dose and over 80% with two doses. It is authorized for adults aged 18 and older, with emergency use granted for high-risk adolescents aged 12 to 17. The vaccine can be stored for up to eight weeks at 2-8 degrees Celsius and has a favorable safety profile with mild to moderate side effects.

What Are Latest Mergers And Acquisitions In The Mvabea Market?

In July 2025, Innosera ApS, a Sweden / UK-based consortium led by private-equity managers Nordic Capital (Sweden) and Permira (UK), providers of buyout and growth-equity investment services, acquired Bavarian Nordic A/S for approximately DKK 19 billion (~US$2.8–3.1 billion) in an all-cash offer. With this acquisition, Innosera ApS aims to take Bavarian Nordic private to accelerate strategic investments in vaccine manufacturing, expand global supply capabilities, and pursue long-term value creation away from public-market pressures. Bavarian Nordic A/S is a Denmark-based provider of vaccine development and manufacturing, including vaccines for smallpox/monkeypox and components relevant to Mvabea.

Regional Insights

North America was the largest region in the mvabea market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Mvabea Market?

The mvabea market consists of sales of ebola vaccine regimens in combination with Zabdeno (Ad26.ZEBOV). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Mvabea Market Report 2026?

The mvabea market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the mvabea industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.